Published in Oncotarget on May 10, 2015
Metformin use and cervical cancer risk in female patients with type 2 diabetes. Oncotarget (2016) 0.82
Early Shifts of Brain Metabolism by Caloric Restriction Preserve White Matter Integrity and Long-Term Memory in Aging Mice. Front Aging Neurosci (2015) 0.81
Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based "starvation" strategies in BRCA1 carriers. Oncotarget (2016) 0.79
Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus. Aging (Albany NY) (2016) 0.78
A weighty problem: metabolic perturbations and the obesity-cancer link. Horm Mol Biol Clin Investig (2015) 0.78
Effects of Metformin and a Mammalian Target of Rapamycin (mTOR) ATP-Competitive Inhibitor on Targeted Metabolomics in Pancreatic Cancer Cell Line. Metabolomics (Los Angel) (2016) 0.77
Buformin exhibits anti-proliferative and anti-invasive effects in endometrial cancer cells. Am J Transl Res (2016) 0.76
Metformin Use Is Associated with Reduced Incidence and Improved Survival of Endometrial Cancer: A Meta-Analysis. Biomed Res Int (2017) 0.75
Functional characterization of AMP-activated protein kinase signaling in tumorigenesis. Biochim Biophys Acta (2016) 0.75
Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer. PLoS One (2017) 0.75
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2014) 40.30
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer (2004) 16.69
AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol (2007) 15.30
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer (2009) 12.92
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A (2004) 12.30
Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science (2004) 11.39
AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell (2005) 11.19
AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol (2012) 10.42
Molecular mediators of hepatic steatosis and liver injury. J Clin Invest (2004) 9.40
Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology (2006) 9.34
The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 7.77
Recent progress in the biology and physiology of sirtuins. Nature (2009) 7.73
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res (2006) 6.99
Senescence in tumours: evidence from mice and humans. Nat Rev Cancer (2010) 6.34
The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol (2007) 6.22
Metformin: an update. Ann Intern Med (2002) 5.62
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res (2007) 5.45
Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med (1995) 5.42
Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci (2004) 4.40
Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) (2010) 4.36
The common biology of cancer and ageing. Nature (2007) 4.28
AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab (2011) 3.98
PI3K/Akt: getting it right matters. Oncogene (2008) 3.91
Ovarian cancer. Lancet (2014) 3.80
AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol (2007) 3.72
An expanding role for mTOR in cancer. Trends Mol Med (2005) 3.40
Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases. Trends Pharmacol Sci (2010) 3.05
Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov (2012) 3.02
SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res (2007) 2.98
Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun (2010) 2.97
Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun (2001) 2.86
Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab (2006) 2.52
AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab (2010) 2.40
VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med (2011) 2.38
SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells. Circ Res (2010) 2.20
SIRT1 and endocrine signaling. Trends Endocrinol Metab (2006) 2.17
Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res (2005) 2.16
Obesity and cancer. Proc Nutr Soc (2008) 2.00
Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia (2011) 2.00
miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem (2011) 1.98
Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res (2009) 1.87
Energy balance, host-related factors, and cancer progression. J Clin Oncol (2010) 1.85
Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci (2007) 1.81
Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer (2012) 1.78
AMP-activated protein kinase: a universal regulator of autophagy? Autophagy (2007) 1.75
LKB1 and AMPK and the cancer-metabolism link - ten years after. BMC Biol (2013) 1.73
Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research. Carcinogenesis (2009) 1.72
A novel inverse relationship between metformin-triggered AMPK-SIRT1 signaling and p53 protein abundance in high glucose-exposed HepG2 cells. Am J Physiol Cell Physiol (2012) 1.62
AMP-activated protein kinase: balancing the scales. Biochimie (2005) 1.50
Inflammation and ovarian cancer. Cytokine (2012) 1.49
Sorting out functions of sirtuins in cancer. Oncogene (2013) 1.47
New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis. Aging (Albany NY) (2012) 1.47
Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer (1995) 1.44
NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget (2011) 1.42
Nutrient regulation of the mTOR complex 1 signaling pathway. Mol Cells (2013) 1.42
Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol (2011) 1.38
Sirtuin catalysis and regulation. J Biol Chem (2012) 1.35
Endometrial cancer, obesity, and body fat distribution. Cancer Res (1991) 1.33
Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol (2012) 1.29
Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J Endocrinol (2010) 1.28
Rapamycin extends life- and health span because it slows aging. Aging (Albany NY) (2013) 1.19
Metformin in cancer prevention and therapy. Ann Transl Med (2014) 1.18
Cellular senescence in the development and treatment of cancer. Curr Pharm Des (2010) 1.17
Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur J Cancer (2012) 1.15
Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine (2012) 1.11
Old drug, new trick: repurposing metformin for gynecologic cancers? Gynecol Oncol (2014) 1.11
The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci (2013) 1.09
Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol (2013) 1.08
Geroconversion: irreversible step to cellular senescence. Cell Cycle (2014) 1.07
Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J Oncol (2010) 1.06
Interleukin-6 serum levels in patients with gynecological tumors. Int J Cancer (1994) 1.05
Energy balance and breast cancer risk. Cancer Epidemiol Biomarkers Prev (2005) 1.05
The role of adiponectin in breast cancer: a meta-analysis. PLoS One (2013) 0.96
Effect of obesity on survival of women with epithelial ovarian cancer: a systematic review and meta-analysis of observational studies. Int J Gynecol Cancer (2011) 0.96
Role of AMP-activated protein kinase in cancer therapy. Arch Pharm (Weinheim) (2014) 0.95
Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias? Gynecol Oncol (2010) 0.94
Caloric restriction: is mammalian life extension linked to p53? Aging (Albany NY) (2012) 0.94
Linking obesity to colorectal cancer: recent insights into plausible biological mechanisms. Curr Opin Clin Nutr Metab Care (2013) 0.93
Metformin limits the adipocyte tumor-promoting effect on ovarian cancer. Oncotarget (2014) 0.93
Effects of energy balance on cancer in genetically altered mice. J Nutr (2004) 0.92
Calorie restriction delays the progression of lesions to pancreatic cancer in the LSL-KrasG12D; Pdx-1/Cre mouse model of pancreatic cancer. Exp Biol Med (Maywood) (2013) 0.91
Direct role of adiponectin and adiponectin receptors in endometrial cancer: in vitro and ex vivo studies in humans. Mol Cancer Ther (2011) 0.89
Molecular Links between Caloric Restriction and Sir2/SIRT1 Activation. Diabetes Metab J (2014) 0.89
Energy balance modulates mouse skin tumor promotion through altered IGF-1R and EGFR crosstalk. Cancer Prev Res (Phila) (2012) 0.87
Mechanisms linking excess adiposity and carcinogenesis promotion. Front Endocrinol (Lausanne) (2014) 0.86
The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications--a review. J Mol Med (Berl) (2013) 0.84
Dietary energy balance modulates ovarian cancer progression and metastasis. Oncotarget (2014) 0.83
Cross-talk between sirtuin and mammalian target of rapamycin complex 1 (mTORC1) signaling in the regulation of S6 kinase 1 (S6K1) phosphorylation. J Biol Chem (2014) 0.81
Metformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer. Biomed Res Int (2014) 0.79
[Effect of paternal drunkenness and smoking on child development]. Pediatriia (1988) 0.76